These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 16884702

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test.
    Ohno Y, Shimizu S, Imaki J, Ishihara S, Sofue N, Sasa M, Kawai Y.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul 01; 32(5):1302-7. PubMed ID: 18495311
    [Abstract] [Full Text] [Related]

  • 3. Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects.
    Carey RJ, DePalma G, Damianopoulos E, Shanahan A, Müller CP, Huston JP.
    Brain Res; 2005 Feb 09; 1034(1-2):162-71. PubMed ID: 15713268
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
    Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P.
    J Pharmacol Exp Ther; 2006 Dec 09; 319(3):1225-34. PubMed ID: 16959959
    [Abstract] [Full Text] [Related]

  • 6. Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal firing of the midbrain raphe nuclei 5-HT neurons and a decrease of their response to 5-HT(1A) receptor stimulation in the rat.
    Wang S, Zhang QJ, Liu J, Wu ZH, Wang T, Gui ZH, Chen L, Wang Y.
    Neuroscience; 2009 Mar 17; 159(2):850-61. PubMed ID: 19174182
    [Abstract] [Full Text] [Related]

  • 7. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
    Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M, Suda T, Matsunaga M.
    No To Shinkei; 2002 Feb 17; 54(2):133-7. PubMed ID: 11889759
    [Abstract] [Full Text] [Related]

  • 8. Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine.
    Sprah L, Zivin M, Sket D.
    J Pharmacol Exp Ther; 1999 Mar 17; 288(3):1093-100. PubMed ID: 10027846
    [Abstract] [Full Text] [Related]

  • 9. [A new approach to innovating selective anxiolytics: pharmacological profile of a novel 5-HT1A agonist (tandospirone)].
    Sasa M.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1997 Apr 17; 17(2):53-9. PubMed ID: 9201724
    [Abstract] [Full Text] [Related]

  • 10. 5-HT1A receptor agonists buspirone and gepirone attenuate apomorphine-induced aggressive behaviour in adult male Wistar rats.
    Pruus K, Skrebuhhova-Malmros T, Rudissaar R, Matto V, Allikmets L.
    J Physiol Pharmacol; 2000 Dec 17; 51(4 Pt 2):833-46. PubMed ID: 11220492
    [Abstract] [Full Text] [Related]

  • 11. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors.
    Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K.
    Eur Neuropsychopharmacol; 2008 Jun 17; 18(6):448-54. PubMed ID: 18164909
    [Abstract] [Full Text] [Related]

  • 12. Analysis of the role of 5-HT1A receptors in spatial and aversive learning in the rat.
    Lüttgen M, Elvander E, Madjid N, Ogren SO.
    Neuropharmacology; 2005 May 17; 48(6):830-52. PubMed ID: 15829255
    [Abstract] [Full Text] [Related]

  • 13. Tandospirone stimulates prolactin secretion in the rat by an action at serotonin-1A receptors.
    Mulroney SE, Skudlarek C, Shemer A, Lumpkin MD, Kellar KJ.
    J Pharmacol Exp Ther; 1994 Feb 17; 268(2):862-7. PubMed ID: 8113999
    [Abstract] [Full Text] [Related]

  • 14. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
    Jones CA, Johnston LC, Jackson MJ, Smith LA, van Scharrenburg G, Rose S, Jenner PG, McCreary AC.
    Eur Neuropsychopharmacol; 2010 Aug 17; 20(8):582-93. PubMed ID: 20434890
    [Abstract] [Full Text] [Related]

  • 15. 5-HT1A receptors in the dorsal hippocampus mediate the anxiogenic effect induced by the stimulation of 5-HT neurons in the median raphe nucleus.
    Dos Santos L, de Andrade TG, Zangrossi Junior H.
    Eur Neuropsychopharmacol; 2008 Apr 17; 18(4):286-94. PubMed ID: 17728111
    [Abstract] [Full Text] [Related]

  • 16. Increased behavioral response to dopaminergic stimulation of the subthalamic nucleus after nigrostriatal lesions.
    Mehta A, Thermos K, Chesselet MF.
    Synapse; 2000 Sep 15; 37(4):298-307. PubMed ID: 10891867
    [Abstract] [Full Text] [Related]

  • 17. Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease.
    Mignon L, Wolf WA.
    Psychopharmacology (Berl); 2007 May 15; 192(1):49-59. PubMed ID: 17265149
    [Abstract] [Full Text] [Related]

  • 18. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux.
    Huang M, Horiguchi M, Felix AR, Meltzer HY.
    Neuroreport; 2012 May 09; 23(7):436-40. PubMed ID: 22415605
    [Abstract] [Full Text] [Related]

  • 19. Involvement of median raphe nucleus 5-HT1A receptors in the regulation of generalized anxiety-related defensive behaviours in rats.
    Vicente MA, Zangrossi H, dos Santos L, de Macedo CE, Andrade TG.
    Neurosci Lett; 2008 Nov 21; 445(3):204-8. PubMed ID: 18789373
    [Abstract] [Full Text] [Related]

  • 20. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W.
    Brain Res Bull; 2006 Apr 14; 69(3):318-26. PubMed ID: 16564428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.